Abstract 897P
Background
Burkitt lymphoma (BL) is recognized as a highly curable disease with intensive chemotherapy protocols. A survival analysis of BL patients treated at our institution with the NHL-BFM 90 protocol was carried out.
Methods
We retrospectively analysed all patients treated with the NHL-BFM 90 protocol at our institute between 2010 and 2020. Only patients with an explicit pathological diagnosis of BL were included. Standard staging and evaluation procedures included bone marrow biopsy, CT scans and cerebrospinal fluid analysis. Data was collected regarding age, stage, unfavourable prognostic factors and performance status according to WHO classification. Additional data on number of treatment cycles, use of rituximab or adjuvant radiotherapy and first line treatment outcome was also gathered. Progression free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method.
Results
Patients’ characteristics of the 26 patients included in the analysis are presented in the table. Median number of treatment cycles was six, and twenty-one patients received rituximab at some point for first-line treatment. Fourteen patients achieved complete remission, six partial remission and required consolidative radiotherapy, whereas four progressed during first-line treatment. Two patients could not be evaluated because they died after the first cycle (1 suicide and 1 death due to septic shock). The estimated 8-year PFS was 95% (95% CI 90,2% - 99,8%), estimated 8-year OS was 64,6% (95% CI 55,1% - 74,1%), while estimated 8-year lymphoma-specific OS was 75,9% (95% CI 67,3% - 84,5%). 6 out of 9 deaths were lymphoma- or treatment-related (4 patients died during first-line chemotherapy, 1 of septic shock and 1 patient relapsed after first-line treatment and died of relapse), 2 patients committed suicide and one died of pneumonia several months after treatment. Table: 897P
| Descriptive data | N= 26 |
| Age, median (range) | 43 years (min 19 – max 70) |
| Stage (I / II / III / IV) | 1 / 2 / 8 / 15 |
| Constitutional symptoms | 8 |
| Normal LDH / Elevated LDH | 5 / 21 |
| BM involvement (present / absent) | 7 / 19 |
| More than 1 extranodal localisation (present / absent) | 18 / 8 |
| CSF involvement (present / absent) | 4 / 22 |
| HIV infection (present / absent) | 1 / 25 |
| PS WHO (0 / 1 / 2 / 3 / 4) | 12 / 7 / 5 / 1 / 1 |
| IPI score (0 / 1 / 2 / 3 / 4 / 5) | 4 / 1 / 4 / 12 / 4 / 1 |
Conclusions
The NHL BFM 90 protocol is an effective option for treatment of adult patients with BL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Lucka Boltezar.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.